聚焦超声脑肿瘤液体活检 (FUS-LBx) 补充剂-猫眼课题宝

聚焦超声脑肿瘤液体活检 (FUS-LBx) 补充剂

批准号：

10448708

负责人：

Hong Chen

金额：

$13.54万

依托单位：

WASHINGTON UNIVERSITY

依托单位国家：

美国

项目类别：

财政年份：

2021

资助国家：

美国

项目状态：

已结题

起止时间：

2021-08-19 至 2024-04-30

来源：

https://reporter.nih.gov/project-details/10448708

关键词：

Address Animals Applications Grants Automobile Driving Biological Markers Biopsy Blood Blood - brain barrier anatomy Blood Circulation Brain Brain Diseases Brain Neoplasms Cardiovascular system Clinical Clinical Management DNA Data Detection Development Devices Diagnosis Disease Excision Family suidae Focused Ultrasound Future Goals Histologic Image Learning Liquid substance Location Magnetic Resonance Imaging Malignant Neoplasms Malignant neoplasm of brain Medical Microbubbles Molecular Molecular Profiling Monitor National Institute of Biomedical Imaging and Bioengineering Operative Surgical Procedures Parents Patient Monitoring Patients Polymerase Chain Reaction Proteins Public Health RNA Research Risk Sampling Small Business Innovation Research Grant Small Business Technology Transfer Research Spectrum Analysis Techniques Tissues Tumor Markers Tumor-Derived United States United States National Institutes of Health Work base clinical translation commercialization controlled release design detection method digital extracellular vesicles liquid biopsy neoplastic cell neuroimaging next generation sequencing novel patient population pre-clinical programs safety and feasibility tool treatment response tumor tumor progression

项目摘要

项目成果

Hong Chen的其他基金

相似基金

相关文献

中文摘要

翻译

项目总结/摘要此应用程序用于NIBIB C3i Accell程序。我们的父R01应用程序的目标（R01EB 030102，项目周期：2020年8月1日至2024年4月30日）进行小动物和大动物研究，获得支持聚焦超声的未来临床转化所需的令人信服的临床前证据，液体活组织检查（声活检）。通过从NIBIB的C3i项目中学习，我们确定了一个关键风险为了使我们的技术商业化，需要优化声活检装置的设计并验证了其生物标志物释放的可行性和安全性。我们提出的目标是 C3i Accell计划的研究就是为了解决这一关键技术风险。这项工作的顺利完成将获得数据，将支持我们的初创公司的NIH SBIR/STTR赠款申请，以进一步商业化发展努力。

英文摘要

PROJECT SUMMARY/ABSTRACT This application is for the NIBIB C3i Accell program. The objective of our parent R01 application (R01EB030102, Project Period: 08/01/2020–04/30/2024) is to perform small animal and large animal studies to obtain compelling preclinical evidence needed to support future clinical translation of focused ultrasound-enabled liquid biopsy (sonobiopsy). Through learnings from NIBIB’s C3i programs, we identified that one key risk toward commercialization of our technique is the need to optimize the design of the sonobiopsy device for clinical use and validated its feasibility and safety in biomarker release. The objective of our proposed research for the C3i Accell program is to address this key technical risk. Successful completion of this work will obtain data that will support our start-up company’s NIH SBIR/STTR grant application to further commercial development efforts.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文